Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) D ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Priyam Shah - Investor Relations Brian McKelligon - Chief Executive Officer John Ek - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Mason Carrico - Stephens Inc Ruizhi Qin - JPMorgan Vivian Bais - BTIG Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Lucas Baranowski - UBS Operator Good day and thank you for standing by. Welcome to the Akoya Biosc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Joe Driscoll - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Kyle Mikson - Canaccord Mason Carrico - Stephens Tejas Savant - Morgan Stanley Mark Massaro - BTIG David Westenberg - Piper Sandler Tim Chiang - Capital One Operator Thank you for standing by. And welcome to the Akoya Bioscie ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 (Address of principal executive offices) (Zip Code) (855) 896-8401 Registrant's tele ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Priyam Shah - Senior Director, Investor Relations Brian McKelligon - Chief Executive Officer Joseph Driscoll - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens Mark Massaro - BTIG Neil Vibhakar - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all partici ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joseph Driscoll - CFO Conference Call Participants Neil Vibhakar - Morgan Stanley Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG David Westenberg - Piper Sandler Operator Thank you for standing by, and welcome to the Akoya Biosciences Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. Af ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) 4 ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joe Driscoll - CFO Conference Call Participants Dave Westenberg - Piper Sandler Edmund Tu - Morgan Stanley Operator Welcome to the Akoya Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. I would now like to turn the conference over to your host, Mr. Priyam Shah, Head of ...